A new trading day began on Friday, with Cytek BioSciences Inc (NASDAQ: CTKB) stock price up 3.34% from the previous day of trading, before settling in for the closing price of $4.95. CTKB’s price has ranged from $3.80 to $9.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 36.02% over the last five years. Meanwhile, its annual earnings per share averaged -89.56%. With a float of $119.40 million, this company’s outstanding shares have now reached $130.71 million.
The firm has a total of 676 workers. Let’s measure their productivity. In terms of profitability, gross margin is 54.97%, operating margin of -13.06%, and the pretax margin is -8.22%.
Cytek BioSciences Inc (CTKB) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Cytek BioSciences Inc is 9.21%, while institutional ownership is 56.94%. The most recent insider transaction that took place on Apr 19 ’24, was worth 117,400. In this transaction CHIEF TECHNOLOGY OFFICER of this company sold 20,000 shares at a rate of $5.87, taking the stock ownership to the 5,988,502 shares. Before that another transaction happened on Apr 09 ’24, when Company’s CHIEF TECHNOLOGY OFFICER sold 1,900 for $7.00, making the entire transaction worth $13,304. This insider now owns 6,008,502 shares in total.
Cytek BioSciences Inc (CTKB) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around -89.56% per share during the next fiscal year.
Cytek BioSciences Inc (NASDAQ: CTKB) Trading Performance Indicators
Here are Cytek BioSciences Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.51. Likewise, its price to free cash flow for the trailing twelve months is 63.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.13, a number that is poised to hit 0.01 in the next quarter and is forecasted to reach 0.13 in one year’s time.
Technical Analysis of Cytek BioSciences Inc (CTKB)
Analysing the last 5-days average volume posted by the [Cytek BioSciences Inc, CTKB], we can find that recorded value of 0.48 million was lower than the volume posted last year of 0.67 million. As of the previous 9 days, the stock’s Stochastic %D was 52.57%. Additionally, its Average True Range was 0.23.
During the past 100 days, Cytek BioSciences Inc’s (CTKB) raw stochastic average was set at 19.48%, which indicates a significant decrease from 55.56% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 38.58% in the past 14 days, which was lower than the 58.84% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.21, while its 200-day Moving Average is $6.23. Now, the first resistance to watch is $5.24. This is followed by the second major resistance level at $5.38. The third major resistance level sits at $5.52. If the price goes on to break the first support level at $4.96, it is likely to go to the next support level at $4.82. Now, if the price goes above the second support level, the third support stands at $4.68.
Cytek BioSciences Inc (NASDAQ: CTKB) Key Stats
With a market capitalization of 694.41 million, the company has a total of 131,506K Shares Outstanding. Currently, annual sales are 193,020 K while annual income is -12,150 K. The company’s previous quarter sales were 46,620 K while its latest quarter income was -10,430 K.
